CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer?
作者信息
Ziogas Dimosthenis, Roukos Dimitrios H
出版信息
Ann Surg Oncol. 2009 Oct;16(10):2678-81. doi: 10.1245/s10434-009-0598-y. Epub 2009 Jul 28.
Abstract
摘要
相似文献
1
CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer?
Ann Surg Oncol. 2009 Oct;16(10):2678-81. doi: 10.1245/s10434-009-0598-y. Epub 2009 Jul 28.
2
Early genetic counseling and detection of CDH1 mutation in asymptomatic carriers improves survival in hereditary diffuse gastric cancer.
Surgery. 2018 Oct;164(4):754-759. doi: 10.1016/j.surg.2018.05.059. Epub 2018 Aug 23.
3
Hereditary diffuse CDH1 positive gastric cancer. Prophylactic gastrectomy?
Med Clin (Barc). 2021 Jul 9;157(1):46-48. doi: 10.1016/j.medcli.2020.04.064. Epub 2020 Aug 6.
4
Case report: acute abdominal pain in a 37-year-old patient and the consequences for his family.
BMC Gastroenterol. 2020 May 3;20(1):129. doi: 10.1186/s12876-020-01283-2.
5
Prophylactic total gastrectomy in hereditary diffuse gastric cancer: identification of two novel CDH1 gene mutations-a clinical observational study.
Fam Cancer. 2014 Jun;13(2):231-42. doi: 10.1007/s10689-013-9698-8.
6
An investigation of the factors effecting high-risk individuals' decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC).
Fam Cancer. 2016 Oct;15(4):665-76. doi: 10.1007/s10689-016-9910-8.
7
Is prophylactic gastrectomy indicated for healthy carriers of CDH1 gene mutations associated with hereditary diffuse gastric cancer?
Rev Esp Enferm Dig. 2019 Mar;111(3):189-192. doi: 10.17235/reed.2018.5831/2018.
8
Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery.
Cancer. 2008 Oct 1;113(7 Suppl):1850-6. doi: 10.1002/cncr.23650.
9
[Preventive resection of hereditary diffuse gastric cancer].
Ned Tijdschr Geneeskd. 2006 Nov 4;150(44):2417-20.
10
Total Gastrectomy for CDH-1 Mutation Carriers: An Institutional Experience.
J Surg Res. 2020 Mar;247:438-444. doi: 10.1016/j.jss.2019.09.062. Epub 2019 Nov 1.
引用本文的文献
1
Therapeutic and prophylactic gastrectomy in a family with hereditary diffuse gastric cancer secondary to a CDH1 mutation: a case series.
World J Surg Oncol. 2018 Jul 14;16(1):143. doi: 10.1186/s12957-018-1415-5.
2
Prophylactic Laparoscopic Total Gastrectomy with Jejunal Pouch Reconstruction in Patients Carrying a CDH1 Germline Mutation.
J Gastrointest Surg. 2015 Dec;19(12):2120-5. doi: 10.1007/s11605-015-2963-4. Epub 2015 Oct 6.
3
Synchronous appendiceal and intramucosal gastric signet ring cell carcinomas in an individual with CDH1-associated hereditary diffuse gastric carcinoma: a case report of a novel association and review of the literature.
BMC Gastroenterol. 2013 Jul 12;13:114. doi: 10.1186/1471-230X-13-114.
4
Robotic surgery and limitations.
Surg Endosc. 2012 Feb;26(2):580-1. doi: 10.1007/s00464-011-1894-8.
5
Endoscopic and laparoscopic ultrasonography used to predict tumor staging and improve therapeutic decisions for upper gastrointestinal tract cancer.
Surg Endosc. 2012 Jan;26(1):280-1. doi: 10.1007/s00464-011-1847-2.
6
Robotic versus laparoscopic surgery for rectal cancer and cost-effectiveness analysis.
Surg Endosc. 2011 Dec;25(12):3954-6; author reply 3957-8. doi: 10.1007/s00464-011-1808-9.
7
The identification and management of hereditary diffuse gastric cancer in a large Jordanian family.
Fam Cancer. 2011 Dec;10(4):667-72. doi: 10.1007/s10689-011-9463-9.
8
Sentinel node biopsy in laparoscopic surgical oncology.
Surg Endosc. 2011 Nov;25(11):3713-4. doi: 10.1007/s00464-011-1747-5.
9
Challenges with identification of angiogenesis biomarkers in cancer.
Surg Endosc. 2011 Aug;25(8):2769-70. doi: 10.1007/s00464-011-1623-3.
10
Thoracolaparoscopic esophagectomy: further improvement in the multimodal treatment of esophageal cancer.
Surg Endosc. 2011 Oct;25(10):3466-7. doi: 10.1007/s00464-011-1691-4.
本文引用的文献
1
Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients.
Ann Surg Oncol. 2009 Jul;16(7):1890-5. doi: 10.1245/s10434-009-0471-z. Epub 2009 May 1.
2
Personalized cancer diagnostics and therapeutics.
Expert Rev Mol Diagn. 2009 Apr;9(3):227-9. doi: 10.1586/erm.09.6.
3
Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine.
Expert Rev Mol Diagn. 2009 Apr;9(3):217-21. doi: 10.1586/erm.09.7.
4
Genome-wide association studies: how predictable is a person's cancer risk?
Expert Rev Anticancer Ther. 2009 Apr;9(4):389-92. doi: 10.1586/era.09.12.
5
Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer.
Ann Surg Oncol. 2009 Apr;16(4):795-8. doi: 10.1245/s10434-009-0317-8. Epub 2009 Jan 24.
6
Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention.
Expert Rev Mol Diagn. 2009 Jan;9(1):1-6. doi: 10.1586/14737159.9.1.1.
7
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer.
Nat Genet. 2008 Jun;40(6):730-40. doi: 10.1038/ng.152. Epub 2008 May 18.
8
Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy.
Cancer. 2008 Jun 15;112(12):2655-63. doi: 10.1002/cncr.23501.
9
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer.
JAMA. 2007 Jun 6;297(21):2360-72. doi: 10.1001/jama.297.21.2360. Epub 2007 Jun 3.
10
E-cadherin germline mutations in familial gastric cancer.
Nature. 1998 Mar 26;392(6674):402-5. doi: 10.1038/32918.
Zotero 插件